Dr. Umar Hayat, CEO of Accanito Therapeutics Inc.

𝗖𝗼𝗺𝗶𝗻𝗴 𝗼𝘂𝘁 𝗼𝗳 𝗝𝗣𝗠 𝟮𝟬𝟮𝟲 | the market is clearly rewarding differentiated science and focused execution — exactly where we’ve built our science and foundation. Our conversations this week highlighted strong enthusiasm for programs that pair breakthrough biology with a de‑risked, multi‑shot‑on‑goal strategy, and our platform sits squarely in that category. As capital flows back into high‑quality oncology assets, 𝗪𝗲’𝗿𝗲 𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻𝗲𝗱 𝘁𝗼 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗼𝘂𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆, 𝗽𝘂𝗿𝘀𝘂𝗲 𝗮𝗻 𝗲𝘅𝗽𝗲𝗱𝗶𝘁𝗲𝗱 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗽𝗮𝘁𝗵, 𝗳𝗮𝘀𝘁-𝘁𝗿𝗮𝗰𝗸 𝗖𝗠𝗖 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁, 𝗮𝗻𝗱 𝗱𝗿𝗶𝘃𝗲 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗽𝗵𝗮𝘀𝗲 𝗼𝗳 𝗴𝗿𝗼𝘄𝘁𝗵 for patients, physicians, and investors alike.

𝗔𝗖𝗖𝗔𝗡𝗜𝗧𝗢 𝗜𝗡𝗖. / 𝗚𝗔𝗠-𝟬𝟱 𝗦𝗧𝗔𝗡𝗗𝗦 𝗢𝗨𝗧 𝗕𝗘𝗖𝗔𝗨𝗦𝗘 𝗢𝗙:

🧬 Novel MoA – targeting mitochondrial of cancer cells
🔬 Phase I clinical study ongoing in the U.S.
🎯 Interim Phase 1 data & strategic selection of indication
📈 Clear near-term value inflection based on clinical outcome and regulatory strategy

💡 𝗪𝗲’𝗿𝗲 𝗻𝗼𝘄 𝗲𝗻𝗴𝗮𝗴𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗮 𝘀𝗲𝗹𝗲𝗰𝘁 𝗴𝗿𝗼𝘂𝗽 𝗼𝗳 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 interested in early clinical-stage oncology opportunities with first-in-class mechanisms and defined growth pathways.

📩 𝗖𝗢𝗡𝗧𝗔𝗖𝗧 𝗨𝗦:
📧 uhayat@accanitotx.com
📞 +1-415-686-8822

Dario C. Altieri, M.D.

Dario C. Altieri, M.D. is an internationally recognized cancer biologist and biotech innovator with a distinguished career advancing breakthrough oncology research. He is the Co‑Founder of Accanito Therapeutics, where he applies decades of expertise in cancer biology and translational science to guide the company’s therapeutic strategy.

Dr. Altieri serves as President and CEO of The Wistar Institute, a global leader in cancer and biomedical research, and is Director of the NCI‑designated Ellen and Ronald Caplan Cancer Center. A pioneering scientist, he leads a laboratory focused on the survival mechanisms of tumor cells—work that has identified new therapeutic targets across multiple cancer types and advanced a first‑in‑class anticancer agent into a phase 1 clinical trial.

With more than 260 scientific publications and leadership roles across major academic and research institutions, Dr. Altieri brings unparalleled scientific insight and a lifelong commitment to translating cutting‑edge cancer biology into transformative therapies for patients

Umar Hayat Ph.D.

Umar Hayat, Ph.D. is a seasoned biotech entrepreneur and scientific leader with a distinguished career spanning drug discovery, pharmaceutical development, regulatory strategy, and therapeutic commercialization. As the Founder and CEO of Accanito Therapeutics, Dr. Hayat is advancing a new frontier in oncology through the development of mitochondrial‑targeted cancer therapies.

Dr. Hayat serves as Chairman of Hayat HealthCare Inc., providing strategic leadership to HPC LLC and Trials360 LLC and is the Founder and Managing Partner of Revive Pharma US, a company focused on innovative 505(b)(2) drug‑repurposing programs.

Dr. Hayat’s leadership portfolio includes serving as Chief Technology Officer of Gladius Therapeutics and holding senior scientific and operational roles at Relypsa, Anacor, and Transcept Pharmaceuticals—organizations collectively involved in multibillion‑dollar acquisitions. His contributions have played a pivotal role in the approval and commercialization of several important therapies,

His scientific and operational contributions have supported the approval and commercialization of several important therapies, including Veltassa® for the treatment of hyperkalemia, Intermezzo® for the treatment of middle of the night insomnia (MOTN), Kerydin®, for the treatment of onychomycosisEucrisa® for the treatment of atopic dermatitis, and Unafra® non-Opioid drug for the treatment of post-surgical pain management.

Dr. Hayat holds a Ph.D. in Process Engineering from INP‑Toulouse, France, completed a post‑doctoral fellowship at École Polytechnique de Montréal, Canada and earned an M.Sc. in Chemistry from the University of the Punjab, Pakistan